Lineage Cell Therapeutics Reports Q3 2025 Results

Lineage Cell Therapeutics, Inc. ( (LCTX) ) has released its Q3 earnings. Here is a breakdown of the information Lineage Cell Therapeutics, Inc. presented to its investors.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel allogeneic cell therapies aimed at treating serious medical conditions. The company leverages its proprietary cell-based technology platform to design and manufacture specialized human cells for therapeutic purposes.

In its third quarter of 2025, Lineage Cell Therapeutics reported significant progress in its clinical and operational endeavors. The company highlighted positive results from its RG6501 (OpRegen) Phase 1/2a clinical study, a new collaboration with William Demant Invest for developing ReSonance (ANP1) for hearing loss, and the initiation of a manufacturing scale project for Type 1 Diabetes cell therapy.

Key financial metrics from the quarter included total revenues of $3.7 million, a slight decrease from the previous year, primarily due to lower royalty revenues. Operating expenses decreased marginally to $7.5 million, with research and development expenses seeing a slight increase. The company reported a net loss of $29.8 million, largely influenced by non-cash fair value remeasurement of warrant liabilities.

Strategically, Lineage solidified its manufacturing capabilities, demonstrating the ability to produce millions of doses of cell-based products. The company also launched a new initiative focused on islet cell transplants for Type 1 Diabetes, aiming to overcome commercialization hurdles through large-scale production.

Looking ahead, Lineage Cell Therapeutics plans to continue advancing its strategic initiatives, including collaborations with Roche and Genentech, and pursuing grant funding to support its programs. The company remains focused on leveraging its manufacturing achievements to drive future growth and development in cell therapy solutions.